Muscle wasting market forecast
The muscle wasting disease market is enormous. In fact, the prevalence of muscle wasting is growing world-wide as 1% of the population is estimated to be cachexic and 2% precachexic. These numbers actually underestimate the true market size and do not include many notable disease indications yet there are currently no treatments for muscle wasting. This illustrates an unprecedented market demand.
Muscle wasting negatively impacts patient management, treatment costs, drug responsiveness and quality of life after treatment. It also causes mortality. The cancer drug and treatment market continues to grow aggressively and is predicted to approach $150B by 2023. Although the costs for managing cachexia contribute significantly to this market, current treatments try to restore appetite, but not muscle. Addressing this high-demand market could, therefore, profit patients and investors alike. In fact, 5 year growth and penetration modeling suggests that AVGN7 could generate $1-8B of revenue during this period.
Several high-profile technological advances, together with changes in federal regulations that expedite orphan drug development for rare diseases, have fueled a resurgence in the global muscular dystrophy drug and treatment market. Indeed, the market for Duchenne muscular dystrophy (DMD) is growing at an astonishing compound annual rate of ~160% and will eclipse $1 billion by 2019. Parallel growth in other muscular dystrophy sub-markets is expected thanks to new therapeutics like AVGNF. Combinatorial treatments that include AVGN7 with AVGNF or other therapeutics have even greater potential to help patients while simultaneously driving the market.
The recent market entry of IMLYGIC (Amgen), KYMRIAH (Novartis), LUXTURNA (Spark Therapeutics) and YESCARTA (Kite Pharma) represent the tip of the gene therapy iceberg. Many more gene therapeutics are currently being developed and are fueling remarkable growth within this particular technology-driven market independent of disease indication. Such advances are enabling for smaller biotech companies that need not reinvent the wheel. They also lesson the regulatory burden and recruit investors to a thriving market.
Corporate & investor relations
Investment information can be obtained by email (see below). This includes an executive summary, a detailed business plan and various investment documents for firms and/or individuals. Potential corporate partnerships are also sought for all geographies. Interested parties can use the email address below to contact AAVogen's CBO, Heather Hsu, or Director of Business Development, Jade Brown (see About Us).